$PVCT: Bristol-Myers Visits The Blog, [Yet] Again

Bristol-Myers Europe (specifically, France) visited, looking at a blog post I had written about intralesionally-delivered local agents with potential systemic benefits: PV-10, Allovectin-7 and T-Vec (formerly OncoVEX).

There has been extensive recent media coverage of and discussion about the combination of ipilimumab (Yervoy) with anti-PD-1 (and anti-PDL-1) agents, with Bristol-Myers believed by some to hold the catbird seat when it comes to combining therapies, particularly immunotherapies, together (i.e., ipi + "other stuff").

You will recall Dr. Weber presented in Paris about combination therapies. He is very enthused about PV-10 as both a monotherapy and a combination therapy. Moffitt currently is conducting murine study work into the combinations of PV-10 and {anti-CTLA-4 agents, anti-PD-1 agents, anti-PDL-1 agents, etc.}.

$PVCT: Bristol-Myers Visits The Blog

Just saying...

(Unlike Daiichi Sankyo, I would not reach too much into Bristol-Myers' visit(s) at this point).

Blog Reader Question About $PVCT.OB

Do you have any sources you can share on the compassionate use results that utilize both Yervoy and PV10?

I think

• The compassionate use program has not used the Yervoy/PV-10 combination;
• PV-10 has been successfully utilized in the program after Yervoy failed a patient;
• There is a positive view (how much, widespread and/or consensus-based I cannot say with certainty) in the melanoma community that PV-10 would improve Yervoy to the benefit of patients requiring such a combination; and
• Moffitt has not yet conducted murine study work on the combination, but think they want to do such work at some point.